Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in:

Open Access 01-12-2017 | Commentary

Integrating phosphoproteomics into the clinical management of prostate cancer

Authors: Larry C. Cheng, Victor M. Tan, Shridar Ganesan, Justin M. Drake

Published in: Clinical and Translational Medicine | Issue 1/2017

Login to get access

Abstract

Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
Literature
1.
2.
Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS (2016) Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol 195(5):1444–1452CrossRefPubMed
3.
Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):5501–5511CrossRefPubMedPubMedCentral
4.
Silberstein JL, Pal SK, Lewis B, Sartor O (2013) Current clinical challenges in prostate cancer. Transl Androl Urol. 2(3):122–136PubMedPubMedCentral
5.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215–1228CrossRefPubMedPubMedCentral
6.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243CrossRefPubMedPubMedCentral
7.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648CrossRefPubMed
8.
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685–689CrossRefPubMedPubMedCentral
9.
10.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22CrossRefPubMedPubMedCentral
11.
Cancer Genome Atlas Research Network (2015) Electronic address scmo, cancer genome atlas research N. The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025CrossRef
12.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al (2015) DNA-repair defects and Olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697–1708CrossRefPubMedPubMedCentral
13.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038CrossRefPubMedPubMedCentral
14.
Doroshow JH, Kummar S (2014) Translational research in oncology–10 years of progress and future prospects. Nat Rev Clin Oncol. 11(11):649–662CrossRefPubMed
15.
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P et al (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534(7605):55–62CrossRefPubMedPubMedCentral
16.
Drake JM, Paull EO, Graham NA, Lee JK, Smith BA, Titz B et al (2016) phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell 166(4):1041–1054CrossRefPubMed
17.
18.
Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE et al (2016) Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166(3):755–765CrossRefPubMed
19.
Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S et al (2013) Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA 110(49):E4762–E4769CrossRefPubMedPubMedCentral
20.
Paull EO, Carlin DE, Niepel M, Sorger PK, Haussler D, Stuart JM (2013) Discovering causal pathways linking genomic events to transcriptional states using tied diffusion through interacting events (TieDIE). Bioinformatics 29(21):2757–2764CrossRefPubMedPubMedCentral
21.
Lazo JS, Sharlow ER (2016) Drugging undruggable molecular cancer targets. Annu Rev Pharmacol Toxicol 56:23–40CrossRefPubMed
22.
Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J et al (2013) Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 14(13):1307–1316CrossRefPubMed
23.
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U et al (2016) Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol 34(25):3005–3013CrossRefPubMed
24.
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM et al (2015) A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27(3):397–408CrossRefPubMedPubMedCentral
25.
Lito P, Rosen N, Solit DB (2013) Tumor adaptation and resistance to RAF inhibitors. Nat Med 19(11):1401–1409CrossRefPubMed
26.
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387):100–103CrossRefPubMed
27.
Noujaim J, Payne LS, Judson I, Jones RL, Huang PH (2016) Phosphoproteomics in translational research: a sarcoma perspective. Ann Oncol 27(5):787–794CrossRefPubMed
28.
Wolters DA, Washburn MP, Yates JR 3rd (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 73(23):5683–5690CrossRefPubMed
29.
Riley NM, Coon JJ (2016) Phosphoproteomics in the age of rapid and deep proteome profiling. Anal Chem 88(1):74–94CrossRefPubMed
30.
Ficarro SB, McCleland ML, Stukenberg PT, Burke DJ, Ross MM, Shabanowitz J et al (2002) Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol 20(3):301–305CrossRefPubMed
31.
Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ et al (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23(1):94–101CrossRefPubMed
32.
Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367–1372CrossRefPubMed
33.
MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B et al (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7):966–968CrossRefPubMedPubMedCentral
34.
35.
Karpievitch YV, Dabney AR, Smith RD (2012) Normalization and missing value imputation for label-free LC-MS analysis. BMC Bioinform. 13(Suppl 16):S5CrossRef
36.
Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P et al (2015) Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling. Sci Rep. 5:13099CrossRefPubMedPubMedCentral
37.
Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW et al (2014) Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 13(3):907–917CrossRefPubMedPubMedCentral
38.
Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM et al (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 27(7):633–641CrossRefPubMedPubMedCentral
39.
Guo T, Kouvonen P, Koh CC, Gillet LC, Wolski WE, Rost HL et al (2015) Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med 21(4):407–413CrossRefPubMedPubMedCentral
40.
Jersie-Christensen RR, Sultan A, Olsen JV (2016) Simple and reproducible sample preparation for single-shot phosphoproteomics with high sensitivity. Methods Mol Biol 1355:251–260CrossRefPubMed
Metadata
Title
Integrating phosphoproteomics into the clinical management of prostate cancer
Authors
Larry C. Cheng
Victor M. Tan
Shridar Ganesan
Justin M. Drake
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2017
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-017-0138-5

Other articles of this Issue 1/2017

Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs

  • Open Access
  • Research

RETRACTED ARTICLE: Purified umbilical cord derived mesenchymal stem cell treatment in a case of systemic lupus erythematosus

  • Open Access
  • Case report

Extracellular vesicles: how they interact with endothelium, potentially contributing to metastatic cancer cell implants

  • Open Access
  • Review

The role of heterogeneity in asthma: a structure-to-function perspective

  • Open Access
  • Review

The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

  • Open Access
  • Research

MRI detection of endothelial cell inflammation using targeted superparamagnetic particles of iron oxide (SPIO)

  • Open Access
  • Research